Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Fusion Antibodies Plc ( (GB:FAB) ) is now available.
Fusion Antibodies plc has officially launched its OptiMAL® Human Antibody Discovery platform, which was unveiled at the Antibody Engineering and Therapeutics conference in San Diego. This platform, protected by a US patent, utilizes a synthetic library of antibody sequences and Mammalian Display technology to discover novel human antibodies, potentially accelerating the development of therapeutic antibodies and strengthening Fusion’s position in the antibody discovery industry.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £19.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.
Fusion Antibodies Plc receives an overall stock score of 50, primarily driven by its challenging financial performance and valuation concerns. The company’s ongoing profitability and cash flow issues are significant risks. However, the technical analysis indicates strong bullish momentum, which provides some positive sentiment. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on GB:FAB stock, click here.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Belfast-based contract research organization specializing in antibody engineering services for therapeutic drug and diagnostic applications. Established in 2001 as a spin-out from Queen’s University Belfast, the company provides a wide range of services including antibody generation, development, production, characterization, and optimization. Fusion Antibodies has a strong international client base, including eight of the top 10 global pharmaceutical companies by revenue, and aims to enable pharmaceutical and diagnostic companies to develop innovative products efficiently.
Average Trading Volume: 1,035,277
Technical Sentiment Signal: Buy
Current Market Cap: £21.88M
See more data about FAB stock on TipRanks’ Stock Analysis page.